#Potravitug
#YsiosNews I #Ipsen to acquire our #portfolio company #MemoTherapeutics

🎯 #Potravitug is a first-in-class monoclonal antibody targeting BK polyomavirus infection in #kidney transplant recipients, a serious complication with no approved treatment.

👉 ysioscapital.com/2026/07/01/i...

#vc
July 1, 2026 at 12:15 PM
Big shift: post-transplant viral care. Potravitug (Ipsen×Memo) hints BK polyomavirus may be treatable with targeted monoclonal antibodies — payoff: clearer BD/deal upside if pivotal data reads well. Full breakdown → https://future.xsbrt.com/TransplantAntibodyFuture Replies/saves welcome.
July 2, 2026 at 11:02 PM
new data on potravitug, a drug for bk polyomavirus-associated nephropathy (bkpyvan). this is a tough kidney complication after transplant, with no approved targeted treatments. in a phase 2 trial, 24.
July 4, 2026 at 2:02 AM
Feed: "Clinical Trials Arena"
By: Abigail Beaney on Friday, July 25, 2025
Memo advances kidney transplant infection drug despite Phase II miss
Memo Therapeutics will discuss the Phase III trial design for potravitug in kidney transplant infection with regulators by the end of 2025.
www.clinicaltrialsarena.com
July 25, 2025 at 4:35 PM
Ipsen adds a kidney infection drug with its acquisition of Memo Therapeutics.
endpoints.news/ipsen-to-sco...
Ipsen to scoop up Memo Therapeutics and its kidney infection drug
Ipsen buys Memo Therapeutics for €200M upfront, gaining kidney-transplant drug potravitug in its second deal this week.
endpoints.news
July 1, 2026 at 4:15 PM
Memo Therapeutics plans to advance its kidney transplant drug to Phase 3 despite missing its Phase 2 endpoint, arguing the trial set a bar too high for any drug to clear.
Memo Therapeutics says there’s still a path forward for kidney transplant drug that failed Phase 2 trial
Memo Therapeutics advances potravitug for kidney transplant BK virus despite Phase 2 miss; CEO Erik van den Berg cites positive data in nephropathy reduction.
endpoints.news
July 25, 2025 at 4:15 PM
📰 #Finance

"PARIS, FRANCE, 22 JULY 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK polyomavirus monoclonal antibody. About potravitugPotravitug is a…"
Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen’s Rare Disease pipeline
financialpost.com
July 22, 2026 at 6:11 AM
📰 #Finance

"Acquisition focused on clinical-stage program potravitug, a first-in-class BK polyomavirus monoclonal antibody Totality of evidence from the Phase II SAFE KIDNEY II trial supports initiation of pivotal Phase II/III trial later this year Ipsen expands rare disease portfolio to…"
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
financialpost.com
July 1, 2026 at 6:20 AM